LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

LLY

980.18

-2.37%↓

JNJ

227.28

+0.23%↑

ABBV

209.34

-0.51%↓

UNH

386.82

-1.74%↓

AZN

182.68

+0.58%↑

Strona główna・Stock List・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Open

SectorHealthcare

2.88 -1.03

Buy Sell

Overview

Share price change

24h

Current

Min

2.86

Max

2.95

Key metrics
By Trading Economics
Income	4.1M -5.7M
Employees	34
EBITDA	3.1M -6.8M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+587.29% upside

Dividends
By Dow Jones
Next Earnings	19 maj 2026

Market Stats
By TradingEconomics
Market Cap	-88M 300M
Previous open	3.91
Previous close	2.88

News Sentiment

By Acuity

50%

136 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

8.275 / 9.312 Support & Resistance

Anavex Life Sciences Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 maj 2026, 23:53 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 maj 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 maj 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 maj 2026, 23:07 UTC

Acquisitions, Mergers, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 maj 2026, 23:05 UTC

Acquisitions, Mergers, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 maj 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 maj 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 maj 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Price Target

By TipRanks

587.29% upside

12 Months Forecast

Average 20 USD 587.29%

High 20 USD

Low 20 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Anavex Life Sciences Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.275 / 9.312Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

136 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.